$13.60
0.000.00%
At close: -
$13.84
0.241.76%
After Hours: 7:25 PM EDT
Comments
Loading...
Teva Pharmaceutical Indus Analyst Ratings and Price Targets | NYSE:TEVA | Benzinga
Teva Pharmaceutical Industries Ltd has a consensus price target of $18.8 based on the ratings of 11 analysts. The high is $30 issued by Piper Sandler on January 17, 2025. The low is $10 issued by Morgan Stanley on May 25, 2023. The 3 most-recent analyst ratings were released by B of A Securities, UBS, and Barclays on March 6, 2025, January 30, 2025, and January 30, 2025, respectively. With an average price target of $24.33 between B of A Securities, UBS, and Barclays, there's an implied 75.82% upside for Teva Pharmaceutical Industries Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
UBS
Barclays
Piper Sandler
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Teva Pharmaceutical Indus
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | 44.51% | B of A Securities | Jason Gerberry60% | $23 → $20 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | 95.09% | UBS | Ashwani Verma39% | $30 → $27 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | 87.86% | Barclays | Balaji Prasad51% | $28 → $26 | Maintains | Overweight | Get Alert |
| 01/23/2025 | Buy Now | 116.76% | UBS | Ashwani Verma39% | $28 → $30 | Maintains | Buy | Get Alert |
| 01/17/2025 | Buy Now | 116.76% | Piper Sandler | David Amsellem69% | $23 → $30 | Maintains | Overweight | Get Alert |
| 12/18/2024 | Buy Now | 102.31% | Barclays | Balaji Prasad51% | $25 → $28 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | 80.64% | Barclays | Balaji Prasad51% | $22 → $25 | Maintains | Overweight | Get Alert |
| 10/21/2024 | Buy Now | 30.06% | JP Morgan | Chris Schott59% | $16 → $18 | Maintains | Neutral | Get Alert |
| 09/03/2024 | Buy Now | 87.86% | UBS | Ashwani Verma39% | $24 → $26 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 58.96% | Barclays | Balaji Prasad51% | $21 → $22 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 73.41% | UBS | Ashwani Verma39% | $22 → $24 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 66.18% | Jefferies | Glen Santangelo50% | $19 → $23 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 51.73% | Barclays | Balaji Prasad51% | $20 → $21 | Maintains | Overweight | Get Alert |
| 05/30/2024 | Buy Now | 51.73% | B of A Securities | Jason Gerberry60% | $18 → $21 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 44.51% | Piper Sandler | David Amsellem69% | $19 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 44.51% | Barclays | Balaji Prasad51% | $17 → $20 | Maintains | Overweight | Get Alert |
| 03/08/2024 | Buy Now | 1.16% | JP Morgan | Chris Schott59% | → $14 | Upgrade | Underweight → Neutral | Get Alert |
| 02/12/2024 | Buy Now | 37.28% | Piper Sandler | David Amsellem69% | $12 → $19 | Upgrade | Neutral → Overweight | Get Alert |
| 02/05/2024 | Buy Now | -20.52% | Goldman Sachs | Nathan Rich44% | $10 → $11 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 22.83% | Barclays | Balaji Prasad51% | $15 → $17 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | 8.38% | Barclays | Balaji Prasad51% | $14 → $15 | Maintains | Overweight | Get Alert |
| 01/23/2024 | Buy Now | 1.16% | Jefferies | Glen Santangelo50% | $10 → $14 | Upgrade | Hold → Buy | Get Alert |
| 01/03/2024 | Buy Now | -13.29% | Piper Sandler | David Amsellem69% | $8 → $12 | Upgrade | Underweight → Neutral | Get Alert |
| 12/18/2023 | Buy Now | -6.07% | HSBC | Rajesh Kumar63% | → $13 | Initiates | → Buy | Get Alert |
| 11/27/2023 | Buy Now | -6.07% | UBS | Ashwani Verma39% | $11 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 09/20/2023 | Buy Now | -20.52% | UBS | Ashwani Verma39% | $8 → $11 | Maintains | Neutral | Get Alert |
| 09/08/2023 | Buy Now | -6.07% | B of A Securities | Jason Gerberry60% | $12 → $13 | Maintains | Buy | Get Alert |
| 07/06/2023 | Buy Now | -42.2% | UBS | Ashwani Verma39% | $7 → $8 | Upgrade | Sell → Neutral | Get Alert |
| 05/25/2023 | Buy Now | -27.75% | Morgan Stanley | Thibault Boutherin1% | → $10 | Initiates | → Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat42% | — | Upgrade | In-Line → Outperform | Get Alert |
| 05/11/2023 | Buy Now | -20.52% | B of A Securities | Jason Gerberry60% | $13 → $11 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | 1.16% | Barclays | Balaji Prasad51% | $13 → $14 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | -13.29% | Jefferies | Glen Santangelo50% | $10 → $12 | Downgrade | Buy → Hold | Get Alert |
| 11/23/2022 | Buy Now | -49.42% | Piper Sandler | David Amsellem69% | $8 → $7 | Maintains | Underweight | Get Alert |
| 11/14/2022 | Buy Now | -27.75% | JP Morgan | Chris Schott59% | $11 → $10 | Downgrade | Neutral → Underweight | Get Alert |
| 11/07/2022 | Buy Now | -27.75% | BMO Capital | Gary Nachman57% | $11 → $10 | Maintains | Market Perform | Get Alert |
| 10/21/2022 | Buy Now | -27.75% | Jefferies | Glen Santangelo50% | → $10 | Assumes | → Buy | Get Alert |
| 08/05/2022 | Buy Now | -6.07% | B of A Securities | Jason Gerberry60% | $10 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2022 | Buy Now | -27.75% | Goldman Sachs | Nathan Rich44% | $9 → $10 | Maintains | Neutral | Get Alert |
| 06/14/2022 | Buy Now | -27.75% | UBS | Ashwani Verma39% | → $10 | Initiates | → Neutral | Get Alert |
| 05/17/2022 | Buy Now | -34.97% | B of A Securities | Jason Gerberry60% | → $9 | Upgrade | Underperform → Neutral | Get Alert |
| 05/12/2022 | Buy Now | -34.97% | Goldman Sachs | Nathan Rich44% | $10 → $9 | Maintains | Neutral | Get Alert |
| 05/04/2022 | Buy Now | -49.42% | Piper Sandler | David Amsellem69% | $11 → $7 | Downgrade | Neutral → Underweight | Get Alert |
FAQ
What is the target price for Teva Pharmaceutical Indus (TEVA) stock?
The latest price target for Teva Pharmaceutical Indus (NYSE:TEVA) was reported by B of A Securities on March 6, 2025. The analyst firm set a price target for $20.00 expecting TEVA to rise to within 12 months (a possible 44.51% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Teva Pharmaceutical Indus (TEVA)?
The latest analyst rating for Teva Pharmaceutical Indus (NYSE:TEVA) was provided by B of A Securities, and Teva Pharmaceutical Indus maintained their buy rating.
When was the last upgrade for Teva Pharmaceutical Indus (TEVA)?
The last upgrade for Teva Pharmaceutical Industries Ltd happened on March 8, 2024 when JP Morgan raised their price target to $14. JP Morgan previously had an underweight for Teva Pharmaceutical Industries Ltd.
When was the last downgrade for Teva Pharmaceutical Indus (TEVA)?
The last downgrade for Teva Pharmaceutical Industries Ltd happened on January 19, 2023 when Jefferies changed their price target from $10 to $12 for Teva Pharmaceutical Industries Ltd.
When is the next analyst rating going to be posted or updated for Teva Pharmaceutical Indus (TEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating Teva Pharmaceutical Indus (TEVA) correct?
While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a maintained with a price target of $23.00 to $20.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $13.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.